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Previewswith regard to the precise localization of
DC subsets within the tumor bed. Broz
et al. (2014) found that both CD11b+
DC1 and CD103+ DC2 were preferentially
located in collagen-rich zones distal to the
tumor nodules where TAM1 and TAM2
cells were found. In contrast, Ruffell
et al. (2014) report that CD103+ cells
were dispersed throughout the tumor
stroma in the proximity of macrophages.
Although Ruffell et al. (2014) found
no change in the localization of CD103+
cells after treatment with paclitaxel and
aCSF-1, Ma et al. (2013) found that
CD11b+ cells exhibited a selective
tropism for dying tumor cells after doxoru-
bicin treatment.
Irrespective of these discrepancies,
however, the accumulating evidence sug-
gests that some DC subpopulations can
cross-present tumor antigens within the
cancer without needing to migrate to
lymph nodes. Thus, lymphadenectomy
fails to affect the anticancer immune
response elicited by anthracycline-basedchemotherapy (Ma et al., 2013, 2014).
Moreover, direct purification of intratu-
moral DC subsets yields functional tumor
antigen-presenting cells that are able to
prime naive T cells in vitro (Broz et al.,
2014) and elicit anticancer immune
response upon adoptive transfer in vivo
(Ma et al., 2013). These results reinforce
the idea that the tumormay be considered
as a full-blown lymphoid organ, in which
all steps of cellular immune responses
starting with appropriate presentation of
tumor antigens by dendritic cells occur
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In this issue of Cancer Cell, Garsed and colleagues combine chromosome flow sorting and deep sequencing
to characterize the structure of oncogene-containing neochromosomes in liposarcoma and provide evidence
that they are generated by a combination of multiple dynamic and destructive processes.Loss of genomic integrity in cancer has
many differentmanifestations. In this issue
ofCancer Cell, Garsed et al. (2014) investi-
gate one of the most convoluted products
of this genomic instability—the neochro-
mosome, characteristic of well-differenti-
ated/dedifferentiated liposarcoma (WD/
DDLPS). The term ‘‘neochromosome’’ de-
scribes a marker chromosome whose
origin cannot be determined by conven-
tional chromosome banding techniques,
which emphasizes their extreme diver-
gence in size and structure from anynormal chromosome. By combining
chromosome flow sorting and deep
sequencing, Garsed et al. (2014) charac-
terize the structure of these remarkably
large and highly rearranged structures
and propose a model for their genesis
and growth. Undergoing multiple rounds
of such catastrophic events as chromo-
thripsis, breakage-fusion-bridge cycles,
and centromere erosion, their survival is a
testament to the power of selection and
theability of tumors to leveragedestructive
processes for their own benefit.The heterogeneous collection of malig-
nant tumors of adipose tissue known as
liposarcomas constitutes roughly 20% of
all sarcomas (Dei Tos, 2014). The most
common subtype of liposarcoma, ac-
counting for nearly half of all cases, is the
WD/DDLPS, also referred to as atypical
lipomatous tumor in some circumstances.
Although the higher grade DDLPS is
metastatic in roughly 20% of cases, the
primary difficulty of this malignancy is
associated with local aggressiveness
and recurrence. Early cytogenetic studiesovember 10, 2014 ª2014 Elsevier Inc. 593
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Previewsof WD/DDLPS tumors revealed the strik-
ing, consistent presence of ring or giant
marker chromosomes (Dei Tos, 2014), a
feature now recognized as characteristic
of the disease. These neochromosomes
were subsequently shown to contain
high-level amplifications of chromosome
12 region q13-q15 (Dei Tos, 2014), and
further mapping pointed to the proto-on-
cogenes MDM2 and CDK4 (Berner et al.,
1996; Nilbert et al., 1994). Mdm2 inhibits
p53-mediated apoptosis and arrest while
Cdk4 phosphorylation of Rb1 blocks its
interaction with E2F transcription factors
governing the G1-S checkpoint. Thus,
this co-amplification provides a selective
benefit by coordinating increased survival
and proliferation.
While the selective benefit of amplifying
12q13-15 may appear straightforward,
the exact structure of this neochromo-
some and the mechanism by which it
develops has remained a mystery. The
WD/DDLPS neochromosomes contain
so much genetic material that they are,
in fact, the largest chromosomes in the
tumor cells. Garsed et al. (2014) begin
by leveraging this to separate the neo-
chromosomes from the rest of the chro-
mosome complement by flow-sorting
multiple WD/DDLPS cell lines. Consistent
with the neochromosome being the most
remarkable cytogenetic finding in such tu-
mors, copy number analysis shows that
nearly all of the amplified genetic material
in the cell occurs on the neochromosome.
Garsed et al. (2014) then use high-depth
paired-end sequencing of the enriched
neochromosomes to identify how they
are stitched together. While each neo-
chromosome is unique, they share
several features. First, they each contain
a ‘‘core’’ of highly, but unequally, ampli-
fied material from hundreds of genomic
loci. Across cell lines, Garsed et al.
(2014) found that the median length of
the donor sequence is 23 Mb, which is
amplified on average 10-fold, with some
loci amplified considerably more. While
each neochromosome incorporates and
amplifies many different genomic regions,
the only shared sequence across all the
neochromosomes is 1.4 Mb from chro-
mosome 12, which includes MDM2,
CDK4, and several other genes.
Garsed et al. (2014) proceed to utilize
the information in paired-end sequencing
both to reveal the composition as well as
to model the temporal ordering of struc-594 Cancer Cell 26, November 10, 2014 ª20tural rearrangements (Greenman et al.,
2012; Sanborn et al., 2013) in the WD/
DDLPS neochromosomes. The life history
that emerges from these WD/DDLPS
neochromosomes is apparently a tale
of disaster upon disaster; it is quite sur-
prising that anything functional, let alone
beneficial for the cell, can be so created.
The initial episomal structure appears
to have been generated by stitching
together some of the donor loci, including
the chromosome 12 regions, in a nonam-
plifying process highly reminiscent of
chromothripsis (Stephens et al., 2011).
The inferred double minutes apparently
continue to receive donor sequences
through additional chromothripsis, but
the second stage of their development
is dominated by progressive amplifica-
tion and deletion of material through
breakage-fusion-bridge cycles. While
generation of double minutes by chromo-
thripsis has been demonstrated previ-
ously (Sanborn et al., 2013; Stephens
et al., 2011), Garsed et al.’s model for as-
sembly and amplification of the initial
episomal structures to the much larger
neochromosome is novel. While typical
double minutes do not contain centro-
meres and sort randomly to daughter cells
at division, the centromere biology of
these evolving WD/DDLPS neochromo-
somes is apparently quite dynamic. Stan-
dard alphoid centromeres are acquired
but then degraded and lost, while neo-
centromeres are established at other
loci, including across rearrangement
junctions on the neochromosomes.
The final, stabilizing event for the neo-
chromosomes appears to be linearization
and telomere acquisition. While both cir-
cular and linear forms of the neochromo-
somes are often found in WD/DDLPS
tumors, these cell lines contain only linear
forms. Linearization appears to be a late
event and is accomplishedwith the acqui-
sition, but not amplification, of large telo-
meric fragments from diverse donor chro-
mosomes. These additional sequences
extend the length of the neochromo-
somes by over 100 Mb.
Garsed et al. (2014) provide a compel-
lingdescriptionof thearchitecture of these
neochromosomes, and the proposed
model of their genesis and development
is also highly consistentwith the sequence
data. Unfortunately, there is no experi-
mental model in which the process of
12q-containing neochromosome devel-14 Elsevier Inc.opment can be studied in living cells, and
the scopeof neochromosomesequencing
is limited to relatively few cell culture sour-
ces. Therefore, of necessity, the exact na-
ture of the earliest events in this process
remains inferential. However, the general-
ity of the structural model presented by
Garsed et al. (2014) could be tested by
whole genome sequencing of tumor
DNA samples if it becomes practical to
assemble chromosomes de novo with
the development of improved long read
sequencing technologies. Other ques-
tions also remain. How is chromothripsis
initiated, and why is neochromosome for-
mation so strongly associatedwith certain
types of cancer?MDM2 andCDK4 ampli-
fication as doubleminutes or recognizable
insertions inother chromosomesoccurs in
many different types of cancer, but 12q-
containing neochromosomes are much
more restricted. Intriguingly, they are
particularly enriched in malignant, but
typically less metastatic, sarcomas such
as WD/DDLPS and parosteal osteosar-
coma (O¨rndal et al., 1992).What favors as-
sembly of chromosome fragments into
large structures specifically in these histo-
types, and precisely how does this occur?
Is there an underlying susceptibility to this
type of genomic instability in the mesen-
chymal lineage that gives rise to these tu-
mors that could be defined biochemically
(Crasta et al., 2012)? Conversely, do these
cells experience an elevated selective
benefit for this type of structure? The
inactivation of p53 prior to catastrophic
genomic processes such as chromothrip-
sis has been demonstrated before
(Rausch et al., 2012). In these cases, it is
thought that the initial TP53 mutation
either facilitates the initiation of or survival
after chromothripsis. In WD/DDLPS, how-
ever, it appears that chromothripsis pre-
cedes and, in fact, leads to p53 inhibition.
Finally, if the process of neochromosome
formation is so turbulent and dynamic,
why are the other chromosomes relatively
spared? Is the specificity for chromosome
12 completely explained by selection for
12q genes, or are there structural factors
that confer a predilection to this process?
The thought-provoking study by Garsed
et al. (2014) has made significant
inroads into the long-standing problem of
the chromosome mechanics underlying
12q-amplification in WD/DDLPS and will
certainly stimulate additional investigation
of this remarkable phenomenon.
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In this issue of Cancer Cell, Riggi and colleagues use a genomic approach to define two distinct molecular
mechanisms through which the chimeric EWS/FLI1 oncoprotein regulates target genes in Ewing sarcoma,
expanding a framework upon which to model the target gene network and test strategies for antagonizing
growth of this tumor.Twenty two years ago, Delattre and
Thomas pried open the door on Ewing
sarcoma biology by reporting that the
t(11,22) found in the large majority of
these tumors created a fusion gene be-
tween EWS and FLI1 (Delattre et al.,
1992). Finally, there was an unambiguous
biomarker for a malignancy that, up until
then, had been diagnosed primarily by
exclusion. Of even greater importance
was the prevalent belief that a somatic
mutation that was present in 85% of Ew-
ing tumors must be playing crucial onco-
genic roles. This contention was quickly
born out. Not only could ectopic expres-
sion of EWS/FLI1 avidly transform cells,
but inhibition of the fusion consistently
induced growth arrest of Ewing sarcoma
tumor derived cell lines. Who could ask
for a better therapeutic target for this
deadly disease?
And then things got difficult. Structural
function analyses of EWS/FLI1 indicated
that the fusion was mediating its biologic
effects by acting as an aberrant transcrip-tion factor. However, the portion of EWS
that was fused to FLI1 was found to be un-
structured, making it poor bait for protein
interaction screens and a difficult target
to develop small molecule antagonists
against (Ng et al., 2007). EWS/FLI1, like
many of the oncogenic chimeric fusions
found in other sarcomas, earned the ‘‘un-
druggable’’ label. The fact that in the last
two decades there has been only one
candidate small molecule that specifically
targets the EWS/FLI1 fusion, suggests
that, at least so far, this reputation is
deserved (Barber-Rotenberg et al., 2012).
So, if directly antagonizing EWS/FLI1
seemed unfeasible, perhaps targeting
genes that were transcriptionally modu-
lated by the fusion would be a therapeuti-
cally more tractable strategy. As molecu-
lar methods advanced, the number of
EWS/FLI1 target genes that were identi-
fied geometrically increased. The prob-
lem was that demonstrating biologic
relevance of these candidates proved to
be labor intensive, unpredictable, andincomplete. In general, forced expression
of any single EWS/FLI1 target gene did
not recapitulate the EWS/FLI1 phenotype
in cells. Conversely, target gene inhibition
frequently did not completely shut down
the cell transformation effects of EWS/
FLI1.
This suggested that EWS/FLI1 trans-
formed cells through the cumulative effect
of transcriptionally modulating a network
of genes. Inherent in such systems is a
central robustness that can tolerate loss
of oneormorenodeswhile stillmaintaining
the overall effect of the network (Friedman
and Perrimon, 2007). As success in the
search for EWS/FLI1’s Achilles heel was
proving progressively more unlikely, the
need to generate a comprehensive map
of the target gene network became more
urgent. Although earlier work provided
snapshots of this network, it was difficult
to paste the pictures together into a
coherent whole. What was needed was a
wide-angle lens through which to view
the broad EWS/FLI1 target gene network.ovember 10, 2014 ª2014 Elsevier Inc. 595
